The nuclear protein charged amino acid-rich leucine zipper 1 (Crlz-1) has been shown to play a role in the rapid proliferative stages of B-cell development, being targeted by the canonical Wnt/β-catenin signaling pathway.
Epstein-Barr virus (EBV), a member of the herpesvirus family, is a highly common human pathogen that can remain latent in B lymphocytes after the primary infection. Although this latent state is frequently asymptomatic, in some cases, it can lead to the development of malignancies such as Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and some gastric cancer subtypes.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moiety covalently linked to a Bruton tyrosine kinase (BTK) and eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety through a linker reported to be useful for the treatment of cancer, anemia, transplant rejection, neurodegeneration, infections, autoimmune, inflammatory and metabolic disorders.
Nihon Medi-Physics Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising a peptide-modified antibody targeting B-lymphocyte antigen CD20 covalently linked to a radionuclide-chelating agent through a linker reported to be useful for the diagnosis and treatment of cancer.
